PBS updates

Venclexta (Venetoclax)

venetoclax 100 mg tablet, 120 · ORAL · PBS code 12803W

AUTHORITY_REQUIRED

What it costs

AU$7241.87 PBS-determined price per 120 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2021-12-01.
  • • Repeats: 2.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Acute Myeloid Leukaemia


The condition must be previously untreated at the time of initiation with this drug (except for essential treatment with hydroxyurea or leukapheresis); AND

Patient must not be considered eligible for standard intensive remission induction chemotherapy at the time of initiation with this drug; AND

The treatment must be used in combination with azacitidine (refer to Product Information for timing of azacitidine and venetoclax doses); AND

Patient must not have progressive disease while receiving PBS-subsidised treatment with this drug for this condition; AND

The condition must not be acute promyelocytic leukaemia.

Progressive disease monitoring via a complete blood count must be taken at the end of each cycle.

If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles.

Sponsor: AbbVie Pty Ltd ABN 48 156 384 262

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.